Blockade of Endothelin-1 Release Contributes to the Anti-Angiogenic Effect by Pro-Opiomelanocortin Overexpression in Endothelial Cells

Abstract

Pro-opiomelanocortin (POMC) is the precursor of several neuropeptides, such as corticotropin (ACTH), α-melanocyte–stimulating hormone (MSH), and the endogenous opioid, β-endorphin (EP). ACTH-dependent Cushing’s syndrome is characterized by ACTH overproduction and is associated with an increased risk of cardiovascular disease. Endothelial dysfunction has been recognized as an early marker of cardiovascular disease. However, the mechanism underlying endothelial dysfunction by ACTH overexpression in Cushing’s patients remains elusive. Endothelial cells, the primary cells producing endothelin (ET)-1, are both the source and target of POMC-derived peptides. In the present study, we generated adenovirus vectors (Ad) encoding POMC (Ad-POMC) and green fluorescent protein (GFP; Ad-GFP) to investigate whether POMC gene transfer altered the ET-1 homeostasis and angiogenic functions in human EA.hy926 endothelial cells. Via adenovirus gene delivery, the POMC-transduced EA.hy926 cells released significantly elevated ACTH and β-EP levels (P < 0.001). In addition, POMC gene delivery significantly decreased the ET-1 release (P < 0.001) without affecting the ET-1 messenger RNA (mRNA) level. Despite no effect on the secretion of matrix metalloproteinases (MMPs) and cell proliferation, POMC gene delivery significantly inhibited the migration (P < 0.01) and tube-forming capability (P < 0.01) of endothelial cells. Moreover, the POMC-induced inhibition of tube formation could be partially reversed by adding exogenous ET-1 (P < 0.05). In summary, the attenuated ET-1 release and angiogenic processes by POMC overexpression may contribute to endothelial dysfunction, thereby providing a link between Cushing’s syndrome and cardiovascular diseases.

Get full access to this article

View all access options for this article.

References

Mancini T, Kola B, Mantero F, Boscaro M, Arnaldi G.. High cardiovascular risk in patients with Cushing’s syndrome according to 1999 WHO/ISH guidelines. Clin Endocrinol 61:768–777, 2004.

Zetter BR. Angiogenesis and tumor metastasis. Annu Rev Med 49:407–424, 1998.

Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332:411–415, 1988.

Grant K, Loizidou M, Taylor I. Endothelin-1: a multifunctional molecule in cancer. Br J Cancer 88:163–166, 2003.

Goligorsky MS, Budzikowski AS, Tsukahara H, Noiri E. Co-operation between endothelin and nitric oxide in promoting endothelial cell migration and angiogenesis. Clin Exp Pharmacol Physiol 26:269–271, 1999.

Hirata Y, Takagi Y, Fukuda Y, Marumo F. Endothelin is a potent mitogen for rat vascular smooth muscle cells. Atherosclerosis 78:225–228, 1989.

Kirchengast M, Luz M. Endothelin receptor antagonists: clinical realities and future directions. J Cardiovasc Pharmacol 45:182–191, 2005.

Solomon S. POMC-derived peptides and their biological action. Ann N Y Acad Sci 885:22–40, 1999.

Catania A, Gatti S, Colombo G, Lipton JM. Targeting melanocortin receptors as a novel strategy to control inflammation. Pharmacol Rev 56:1–29, 2004.

10.

van Oost BA, Edgell CJ, Hay CW, MacGillivray RT. Isolation of a human von Willebrand factor cDNA from the hybrid endothelial cell line EA.hy926. Biochem Cell Biol 64:699–705, 1986.

11.

Liu GS, Liu LF, Lin CJ, Tseng JC, Chuang MJ, Lam HC, Lee JK, Yang LC, Chan JHY, Howng SL, Tai MH. Gene Transfer of pro-opiomelanocortin prohormone suppressed the growth and metastasis of melanoma: involvement of alpha-MSH-mediated inhibition of NF-kappaB/COX-2 Pathway. Mol Pharm 69:440–451, 2006.

12.

Lam HC, Wei MC, Keng HM, Chu CH, Lee JK, Lu CC, Sun CC, Chuang MJ, Wang MC, Tai MH. The effects of different doses of atorvastatin on plasma endothelin-1 levels in type 2 diabetic subjects. Exp Biol Med (in press), 2006.

13.

Tai MH, Kuo SM, Liang HT, Chio KR, Lam HC, Hsu CM, Pownall HT, Chen HH, Huang MT, Yang CY. Modulation of angiogenic processes in cultured endothelial cells by low density lipoproteins subfractions from patients with familial hypercholesterolemia. Atherosclerosis (in press), 2006.

14.

Scholzen TE, Koenig S, Fastrich M, Böhm M, Luger TA. Production and processing of POMC peptides by dermal microvascular endothelial cells (EC): modulation of EC biologic functions and implication for skin inflammation. Exp Dermatol 14:158–158, 2005.

15.

Wilasrusmee C, Da Silva M, Siddiqui J, Bruch D, Kittur S, Wilasrusmee S, Kittur DS. Role of endothelin-1 in microvascular dysfunction caused by cyclosporin A. J Am Coll Surg 196:584–591, 2003.

16.

Ahmad N, Romero DG, Gomez-Sanchez EP, Gomez-Sanchez CE. Do human vascular endothelial cells produce aldosterone? Endocrinology 145:3626–3629, 2004.

17.

Thomas M, Keramidas M, Monchaux E, Feige JJ. Role of adrenocorticotropic hormone in the development and maintenance of the adrenal cortical vasculature. Microsc Res Tech 61:247–251, 2003.

18.

Huber P, Mallet C, Faure E, Rampon C, Prandini MH, Feraud O, Bouillot S, Vilgrain I. ACTH depletion represses vascular endothelial-cadherin transcription in mouse adrenal endothelium in vivo. J Mol Endocrinol 34:127–137, 2005.

19.

Pasi A, Qu BX, Steiner R, Senn HJ, Bar W, Messiha FS. Angiogenesis: modulation with opioids. Gen Pharmacol 22:1077–1079, 1991.

20.

Dong F, Zhang X, Wold LE, Ren Q, Zhang Z, Ren J. Endothelin-1 enhances oxidative stress, cell proliferation and reduces apoptosis in human umbilical vein endothelial cells: role of ET(B) receptor, NADPH oxidase and caveolin-1. Br J Pharmacol 145:323–333, 2005.

21.

Kirilov G, Tomova A, Dakovska L, Kumanov P, Shinkov A, Alexandrov AS. Elevated plasma endothelin as an additional cardiovascular risk factor in patients with Cushing’s syndrome. Eur J Endocrinol 149:549–553, 2003.

22.

Owen D, Banjanin S, Gidrewicz D, McCabe L, Matthews SG.. Central regulation of the hypothalamic-pituitary-adrenal axis during fetal development in the guinea-pig. J Neuroendocrinol 17:220–226, 2005.

23.

Faggiano A, Pivonello R, Spiezia S, De Martino MC, Filippella M, Di Somma C, Lombardi G, Colao A. Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing’s disease during active disease and 1 year after disease remission. J Clin Endocrinol Metab 88:2527–2533, 2003.